Clinical trials: Prostatic Disease
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among patients with prostate, cervical, and rectal…
- Conditions
- Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05722288
- Testing
- Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
The primary goal of this tissue collection protocol is to establish a framework for the acquisition and banking of biospecimen collected from men undergoing brachytherapy.
- Trial name
- NCT04243473
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adenocarcinoma, Prostate Cancer
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring.
- Conditions
- Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma
- Trial name
- NCT07574541
- Testing
- TriAdeno vaccine, N-803
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
EMBRACE1: Prostate Biorepository
The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for…
- Trial name
- NCT01499381
- Where
- United States
- Volunteers
- 1,290 people
- Sponsor
- Caris Science, Inc.
Prostate Cancer, Urinary Incontinence
The Effects of Pilates in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence
The purpose of this study is to compare the efficacy between a Pilates exercise program and a Pelvic Floor Muscle Training (PFMT) protocol combined with anal electrical stimulation (AES) in muscular pressure strength of the…
- Trial name
- NCT02645136
- Testing
- Pilates, PFMT and AES, Control
- Volunteers
- 115 people
- Sponsor
- Universidade Estadual de Londrina
Prostatic Neoplasms
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
The purpose of this study was to determine the efficacy and safety of oral enzalutamide compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed while on Luteinizing Hormone Receptor Hormone…
- Trial name
- NCT01288911
- Testing
- enzalutamide, bicalutamide
- Where
- 88 sites in United States, Belgium and 6 more
- Volunteers
- 375 people
- Sponsor
- Astellas Pharma Inc
Urothelial Cancer, Bladder Cancer
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Background: Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04235777
- Testing
- Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Breast Adenocarcinoma, Prostate Cancer (Adenocarcinoma)
Personalization of External Beam Radiation Therapy in Localised Tumours
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).
- Trial name
- MINIONS (NCT07047495)
- Testing
- prostate patient, breast patients
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Prostate Cancer
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Brachytherapy, or Transperineal implantation of the prostate (TPIP), is a recognized form of treatment for localized cancer of the prostate. TPIP has been used at the British Columbia Cancer Agency (BCCA) since 1998.
- Trial name
- NCT00175383
- Testing
- luteinizing hormone-releasing hormone (LHRH) short acting or long acting
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Surveillance or Focal Therapy
Patients with newly diagnosed low-intermediate risk prostate cancer often are not advised of all the options in an easy to understand way.
- Trial name
- SOFT (NCT07207902)
- Testing
- Explainer video
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Kaiser Permanente
Prostate Cancer
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
A growing body of literature supports the role of angiogenesis in the development and spread of a variety of human cancers including prostate cancer.
- Trial name
- NCT00945477
- Testing
- Pazopanib (GW786034)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Illinois CancerCare, P.C.
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Prostate Cancer
BKM120+Abiraterone Acetate for Metastatic CRPC
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug, in this case an investigational drug combined with standard drug therapy.
- Trial name
- NCT01741753
- Testing
- BKM120, Abiraterone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
Primary Objective: -Establish the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of weekly mitoxantrone in combination with weekly PS-341 in patients with advanced AI-PCa.
- Trial name
- NCT00059631
- Testing
- Mitoxantrone (Novantrone), Bortezomib (PS-341)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Significant Prostate Cancer
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer.
- Trial name
- NCT03237702
- Testing
- Multi-Carotenoids
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Effectiveness of Community-based Football in Prostate Cancer
Prostate cancer is the most common malignancy in men. Three million are currently living in the United States with the disease and this number is expected to rise to four million in 2024.
- Trial name
- FC-PC (NCT02430792)
- Testing
- Football
- Where
- 4 sites in Denmark
- Volunteers
- 214 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Benign Prostate Hypertrophy(BPH)
Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced…
- Trial name
- NCT07017439
- Testing
- Beta-3 agonists (Mirabegron/Myrbetriq)
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Prostate Cancer, Cancer of Prostate
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
Prostate Stereotactic ablative body radiotherapy (SABR) is an established technique that delivers radiation in a non-invasive approach for men with prostate cancer.
- Conditions
- Prostate Cancer, Cancer of Prostate, Prostate Adenocarcinoma
- Trial name
- iSMART (NCT05600400)
- Testing
- Stereotactic Ablative Body Radiation
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- Sunnybrook Health Sciences Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.